{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$9.18B vs. cons $9.15B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.32 vs. cons $5.22",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Prolia + XGEVA sales",
      "prediction": "MISS",
      "answer": "pred ~$1.00B vs. cons $1.04B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 total-revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$37.80B midpoint vs. cons $37.85B (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 non-GAAP EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$22.40 midpoint vs. cons $22.45 (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 non-GAAP operating-margin guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~45.5% midpoint vs. cons 45.5% (FY2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -2.3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.1,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$5.32 EPS result versus $5.22 consensus is likely insufficient to offset a ~$1.00B denosumab result versus $1.04B consensus and unchanged $37.80B revenue / $22.40 EPS FY2026 guide versus $37.85B / $22.45B consensus; the lack of an out-period raise should prompt modest 2026-2027 estimate cuts.",
  "day5_confidence": "MEDIUM"
}